Contemporary management of muscle-invasive bladder cancer

Marc A. Dall'Era, Liang Cheng, Chong Xian Pan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The current standard treatment for muscle-invasive nonmetastatic bladder cancer is neoadjuvant platinum-based chemotherapy followed by radical cystectomy. However, neoadjuvant chemotherapy is not widely accepted even with level 1 evidence. Adjuvant chemotherapy should be discussed if patients have not received neoadjuvant chemotherapy before surgery and have high-risk pathologic features. Although not considered standard of care, bladder-sparing therapy can be considered for highly selected patients and for those medically unfit for surgery. Even though there are no level 1 data, the treatment outcomes for highly select patients given bladder-sparing therapy appear promising, with many patients retaining a functional bladder. Personalized chemotherapy is currently being actively pursued to target the underlying molecular changes and tailor to individual needs.

Original languageEnglish
Pages (from-to)941-950
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume12
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Urinary Bladder Neoplasms
Drug Therapy
Muscles
Urinary Bladder
Cystectomy
Adjuvant Chemotherapy
Standard of Care
Platinum
Therapeutics

Keywords

  • bladder urothelial carcinoma
  • chemotherapy
  • cisplatin
  • personalized chemotherapy
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Contemporary management of muscle-invasive bladder cancer. / Dall'Era, Marc A.; Cheng, Liang; Pan, Chong Xian.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 7, 07.2012, p. 941-950.

Research output: Contribution to journalArticle

Dall'Era, Marc A. ; Cheng, Liang ; Pan, Chong Xian. / Contemporary management of muscle-invasive bladder cancer. In: Expert Review of Anticancer Therapy. 2012 ; Vol. 12, No. 7. pp. 941-950.
@article{d06a20f521ac435cb65ddf8d78df6ad4,
title = "Contemporary management of muscle-invasive bladder cancer",
abstract = "The current standard treatment for muscle-invasive nonmetastatic bladder cancer is neoadjuvant platinum-based chemotherapy followed by radical cystectomy. However, neoadjuvant chemotherapy is not widely accepted even with level 1 evidence. Adjuvant chemotherapy should be discussed if patients have not received neoadjuvant chemotherapy before surgery and have high-risk pathologic features. Although not considered standard of care, bladder-sparing therapy can be considered for highly selected patients and for those medically unfit for surgery. Even though there are no level 1 data, the treatment outcomes for highly select patients given bladder-sparing therapy appear promising, with many patients retaining a functional bladder. Personalized chemotherapy is currently being actively pursued to target the underlying molecular changes and tailor to individual needs.",
keywords = "bladder urothelial carcinoma, chemotherapy, cisplatin, personalized chemotherapy, targeted therapy",
author = "Dall'Era, {Marc A.} and Liang Cheng and Pan, {Chong Xian}",
year = "2012",
month = "7",
doi = "10.1586/era.12.60",
language = "English",
volume = "12",
pages = "941--950",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Contemporary management of muscle-invasive bladder cancer

AU - Dall'Era, Marc A.

AU - Cheng, Liang

AU - Pan, Chong Xian

PY - 2012/7

Y1 - 2012/7

N2 - The current standard treatment for muscle-invasive nonmetastatic bladder cancer is neoadjuvant platinum-based chemotherapy followed by radical cystectomy. However, neoadjuvant chemotherapy is not widely accepted even with level 1 evidence. Adjuvant chemotherapy should be discussed if patients have not received neoadjuvant chemotherapy before surgery and have high-risk pathologic features. Although not considered standard of care, bladder-sparing therapy can be considered for highly selected patients and for those medically unfit for surgery. Even though there are no level 1 data, the treatment outcomes for highly select patients given bladder-sparing therapy appear promising, with many patients retaining a functional bladder. Personalized chemotherapy is currently being actively pursued to target the underlying molecular changes and tailor to individual needs.

AB - The current standard treatment for muscle-invasive nonmetastatic bladder cancer is neoadjuvant platinum-based chemotherapy followed by radical cystectomy. However, neoadjuvant chemotherapy is not widely accepted even with level 1 evidence. Adjuvant chemotherapy should be discussed if patients have not received neoadjuvant chemotherapy before surgery and have high-risk pathologic features. Although not considered standard of care, bladder-sparing therapy can be considered for highly selected patients and for those medically unfit for surgery. Even though there are no level 1 data, the treatment outcomes for highly select patients given bladder-sparing therapy appear promising, with many patients retaining a functional bladder. Personalized chemotherapy is currently being actively pursued to target the underlying molecular changes and tailor to individual needs.

KW - bladder urothelial carcinoma

KW - chemotherapy

KW - cisplatin

KW - personalized chemotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84864616537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864616537&partnerID=8YFLogxK

U2 - 10.1586/era.12.60

DO - 10.1586/era.12.60

M3 - Article

VL - 12

SP - 941

EP - 950

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 7

ER -